Sanofi (NASDAQ:SNY) Shares Gap Up - Here's What Happened

Sanofi (NASDAQ:SNY - Get Free Report)'s share price gapped up before the market opened on Thursday . The stock had previously closed at $53.95, but opened at $55.66. Sanofi shares last traded at $55.38, with a volume of 328,642 shares traded.

Analysts Set New Price Targets

Several equities research analysts have commented on SNY shares. Sanford C. Bernstein upgraded shares of Sanofi to a "strong-buy" rating in a research note on Thursday, January 30th. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a "sell" rating to a "hold" rating in a report on Thursday, January 30th. The Goldman Sachs Group began coverage on Sanofi in a research report on Friday, March 21st. They issued a "neutral" rating and a $65.00 price objective on the stock. Finally, StockNews.com lowered Sanofi from a "buy" rating to a "hold" rating in a research report on Thursday, December 12th. Three equities research analysts have rated the stock with a hold rating, one has given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $62.50.

Sanofi Trading Down 4.8 %

The firm has a 50 day moving average of $55.37 and a 200 day moving average of $52.68. The firm has a market cap of $131.92 billion, a PE ratio of 20.88, a P/E/G ratio of 1.01 and a beta of 0.57. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15.

Remove Ads

Sanofi (NASDAQ:SNY - Get Free Report) last issued its quarterly earnings results on Thursday, January 30th. The company reported $0.70 EPS for the quarter, meeting analysts' consensus estimates of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. Equities analysts anticipate that Sanofi will post 4.36 earnings per share for the current year.

Hedge Funds Weigh In On Sanofi

Large investors have recently modified their holdings of the business. Synergy Asset Management LLC bought a new position in Sanofi in the 4th quarter worth approximately $25,000. McClarren Financial Advisors Inc. boosted its holdings in shares of Sanofi by 952.6% in the fourth quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company's stock worth $28,000 after acquiring an additional 543 shares during the period. Lee Danner & Bass Inc. purchased a new position in shares of Sanofi in the fourth quarter valued at $31,000. Bessemer Group Inc. grew its position in shares of Sanofi by 59.8% in the fourth quarter. Bessemer Group Inc. now owns 647 shares of the company's stock valued at $32,000 after purchasing an additional 242 shares in the last quarter. Finally, Sunbelt Securities Inc. raised its stake in shares of Sanofi by 72.1% during the 3rd quarter. Sunbelt Securities Inc. now owns 747 shares of the company's stock valued at $43,000 after purchasing an additional 313 shares during the period. Hedge funds and other institutional investors own 14.04% of the company's stock.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.